Natera Raises 2026 Revenue Outlook After Record Q2, Shares Surge 21%
NTRA has more than doubled off its 52-week low of $136.21 on elevated volume (1.9× avg).
Summary
Natera raised its full-year 2026 revenue guidance to $2.85B-$2.91B, up from $2.74B-$2.82B, following a Q2 that beat on both top and bottom lines. Revenue jumped 38% to $752.8M, driven by a 57% surge in oncology test volumes and record total test volumes of 1.04 million. The company processed over 1 million tests for the second straight quarter, and gross margins expanded to 64.5%. CEO Steve Chapman said the company is 'clearly on a roll,' citing momentum across oncology, women's health, and organ health. The stock surged 21% to a new 52-week high, with analysts at Evercore ISI, JPMorgan, and Wells Fargo raising price targets. This follows a series of positive regulatory and clinical milestones, including FDA approval for Signatera in bladder cancer and expanded Medicare coverage for Prospera.
At the time of this announcement, NTRA was trading at $320.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.9B. The 52-week trading range was $136.21 to $323.01. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.